United States-based Pfizer and United States-based Merck's Bavencio (avelumab) plus Inlyta (axitinib) has improved median progression-free survival in a renal carcinoma study, it was reported yesterday.
The companies have reported that the combination of Bavencia and Inlyta have significantly increased median progression-free survival by more than five months compared against Sutent as a first-line treatment for patients with advanced renal cell carcinoma (RCC) in the pivotal Javelin Renal 101 trial. The results are from an interim analysis of the trial.
The phase III Javelin Renal 101 study was designed to evaluate the combination of Bavencio plus Inlyta compared with Sutent in 886 patients with earlier untreated advanced RCC. Bavencio plus Inlyta decreased the risk of disease progression or death by 39% in patients with PD-L1-positive tumours, which is a primary endpoint of the study.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study